A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)
作者
Andrew W. Hahn,Jad Chahoud,William Paul Skelton,Ying Yuan,Amado J. Zurita,C. Kovitz,Omar Alhalabi,Matthew T. Campbell,Eric Jonasch,John K. Lin,Meera Desai,Michael Keith San Diego. Santos,Hyunsoo Hwang,Paul G. Corn,Pavlos Msaouel,Nizar M. Tannir
出处
期刊:Annals of Oncology [Elsevier BV] 日期:2025-10-18卷期号:37 (2): 241-249被引量:2